Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus – report of 17 cases and review of the literature

Remission of Incapacitating Acute Cutaneous Lupus Erythematosus in a Patient With Systemic Lupus Erythematosus by B Cell-Depletive Therapy

(2016) Marc R. Kok et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

(2012) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

Rituximab in the Treatment of Bullous Systemic Lupus Erythematosus

(2012) Shamael Alsanafi et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome

(2011) J. Cortés-Hernández et al.   BRITISH JOURNAL OF DERMATOLOGY

Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER)

(2011) JT Merrill et al.   LUPUS

An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA

(2010) D. A. Isenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry

(2010) Benjamin Terrier et al.   ARTHRITIS AND RHEUMATISM

B Cell-Targeted Therapies for Systemic Lupus Erythematosus

(2010) R. John Looney   DRUGS

Cutaneous lupus erythematosus: Update of therapeutic options

(2010) Annegret Kuhn et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Pathogenesis of cutaneous lupus erythematosus: common and different features in distinct subsets

(2010) J. Wenzel et al.   LUPUS

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: The first fifty patients

(2009) Tim Y.-T. Lu et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab

(2009) Violet Kieu et al.   AUSTRALASIAN JOURNAL OF DERMATOLOGY

A case of “refractory” lupus erythematosus profundus responsive to rituximab [case report]

(2009) Adrian McArdle et al.   CLINICAL RHEUMATOLOGY

Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases

(2009) M Ramos-Casals et al.   LUPUS

Successful Treatment of Refractory Skin Manifestations of Systemic Lupus Erythematosus with Rituximab: Report of a Case

(2008) Imad Uthman et al.   DERMATOLOGY

Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases

(2008) Michael Hertl et al.   JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT